Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Debt: 2009-2025

Historic Total Debt for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to $20.0 million.

  • Aytu Biopharma's Total Debt rose 72.24% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.8 million, marking a year-over-year increase of 33.37%. This contributed to the annual value of $20.0 million for FY2025, which is 50.38% up from last year.
  • Latest data reveals that Aytu Biopharma reported Total Debt of $20.0 million as of FY2025, which was up 50.38% from $13.3 million recorded in FY2024.
  • Aytu Biopharma's Total Debt's 5-year high stood at $20.0 million during FY2025, with a 5-year trough of $13.3 million in FY2024.
  • Its 3-year average for Total Debt is $16.5 million, with a median of $16.3 million in 2023.
  • In the last 5 years, Aytu Biopharma's Total Debt spiked by 1,615.68% in 2021 and then decreased by 18.46% in 2024.
  • Over the past 5 years, Aytu Biopharma's Total Debt (Yearly) stood at $16.8 million in 2021, then rose by 7.38% to $18.1 million in 2022, then decreased by 10.04% to $16.3 million in 2023, then dropped by 18.46% to $13.3 million in 2024, then soared by 50.38% to $20.0 million in 2025.